CG Pharmaceuticals Announces the Commencement of Phase 2 Study for Metastatic Pancreatic Cancer
ORINDA, Calif., Nov. 17, 2023. CG Pharmaceuticals announces the commencement of Phase 2 study for metastatic pancreatic ductal adenocarcinoma (PDAC) with the recommended Phase 2 dose (RP2D) of ivaltinostat (ClinicalTrials.gov ID NCT05249101).
The...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Clinical Trials | Pancreas | Pancreatic Cancer | Pharmaceuticals | Study